Novel Device Offers Hope for Lowering Eye Pressure in Children with Glaucoma
BOSTON – A newly approved augmented glaucoma device demonstrated notable reductions in intraocular pressure (IOP) for children diagnosed with glaucoma, according to data presented at the American Academy of Ophthalmology (AAO) 2023 annual meeting. The device, developed by Nova Eye Medical, offers a less invasive alternative to customary surgical interventions for pediatric glaucoma patients.
Glaucoma is a leading cause of childhood blindness, affecting approximately 1 in 10,000 children. Current treatment options, frequently enough involving multiple surgeries, can be complex and carry risks, particularly for young patients. This new device aims to address these challenges by providing a more controlled and adjustable method for lowering IOP, the primary risk factor for glaucoma-related vision loss. The device works by creating microscopic openings in the eye’s trabecular meshwork, improving fluid drainage and reducing pressure.
researchers reported IOP reductions of up to 30% in children treated with the device during a clinical trial. The study, involving 25 pediatric patients with various types of glaucoma, showed sustained pressure control over a 12-month period. “This device represents a significant advancement in the treatment of pediatric glaucoma,” said Dr. David S. Friedman, lead investigator of the study and a pediatric ophthalmologist at Boston Children’s Hospital. “the ability to precisely control IOP with a minimally invasive procedure offers a promising option for preserving vision in these vulnerable patients.”
The device received FDA approval in October 2023 and is now available for use by qualified ophthalmologists. Nova Eye Medical plans to provide thorough training to surgeons on the proper implantation and adjustment techniques. Further studies are underway to evaluate the long-term efficacy and safety of the device, and also its potential request in adults with glaucoma.
